The Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Most Body Mass Index Categories in Type 2 Diabetes: Results of the LEADER and SUSTAIN 6 Trials Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Verma, Subodh; Bain, Stephen; Bhatt, Deepak L.; Leiter, Lawrence A.; Mazer, C. David; McGuire, Darren K.; Pratley, Richard; Zinman, Bernard; Lindberg, Sore; Rasmussen, Soren; Vrazic, Hrvoje; Buse, John

authors

Publication Date

  • November 6, 2018

webpage

published in

category

keywords

  • Body mass index (BMI) and waist circumference
  • Cardiorenal
  • Cardiovascular disease
  • Cardiovascular disease prevention
  • Diabetes (Type II)

volume

  • 138